標(biāo)題：替利組單抗，Teplizumab，CAS: 876387-05-2，AntibodySystem Laboratories

貨號(hào)：DHC27703

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75401.html

別名：A-031 / MGA031, PRV-031, CAS: 876387-05-2

簡(jiǎn)介：MGTeplizumab (MGA-031)是一種Fc受體型、非結(jié)合類型的抗-人CD3的單克隆抗體。Teplizumab 可緩解β細(xì)胞的功能喪失。Teplizumab可用于type 1型糖尿病的研究。

貨號(hào)：DHC27703

產(chǎn)品品牌：Antibodysystem

通用名：Teplizumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：MGA-031 / MGA031, PRV-031

靶點(diǎn);物種：Human CD3E

種類：Humanized

受體鑒定：IgG1-kappa

CAS: 876387-05-2

存儲(chǔ)條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn)：

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. PMID: 32023396
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. PMID: 33658358
Teplizumab. PMID: 36795904
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. PMID: 21719095
Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis. PMID: 33302842
Teplizumab: First Approval. PMID: 36877454
Teplizumab-mzwv. PMID: 36776142
Teplizumab Improves Beta Cell Function, Delays Type 1 Diabetes. PMID: 33847731
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. PMID: 23835333
Teplizumab: type 1 diabetes mellitus preventable? PMID: 37004543
Teplizumab for treatment of type 1 diabetes mellitus. PMID: 22968521
New Frontiers in the Treatment of Type 1 Diabetes. PMID: 31839487
The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes. PMID: 34551936
FDA approves teplizumab: a milestone in type 1 diabetes. PMID: 36436528
Teplizumab therapy for type 1 diabetes. PMID: 20095914
Antibodies to watch in 2023. PMID: 36472472
Antibodies to watch in 2020. PMID: 31847708
Teplizumab approval for type 1 diabetes in the USA. PMID: 36623521
Teplizumab Therapy to Delay the Onset of Type 1 Diabetes. PMID: 37158990
Teplizumab in Relatives at Risk for Type 1 Diabetes. PMID: 31693815
Teplizumab (Tzield) to delay onset of type 1 diabetes. PMID: 36630581
Teplizumab delays onset of type 1 diabetes mellitus. PMID: 31243389
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups. PMID: 32960433
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. PMID: 35316839
What does the licensing of teplizumab mean for diabetes care? PMID: 36999237
Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. PMID: 24517093
Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply. PMID: 31693818
Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. PMID: 34936848
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. PMID: 27161438
Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review. PMID: 36056809
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. PMID: 23801579
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. PMID: 23086558
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. PMID: 22277969
Changing the landscape for type 1 diabetes: the first step to prevention. PMID: 31533907
Recent Advances in Immune-based Therapies for Type 1 Diabetes. PMID: 35533645
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. PMID: 30569273
Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. PMID: 26518356
Association possible entre l’acidocétose diabétique et l’utilisation d’un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabète de type 2. PMID: 34782384
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. PMID: 19443276
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. PMID: 28664195
Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better? PMID: 34261674
Hematopoietic Stem Cells in Type 1 Diabetes. PMID: 34305929
Immunomodulators: Cell savers. PMID: 22616095
Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention. PMID: 31180193
Prevention of type 1 diabetes: where we are and where we are going. PMID: 34286946
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. PMID: 32833543
Biologic therapies in type 1 diabetes: how far are they from us? PMID: 24229664
Immunotherapies in diabetes mellitus type 1. PMID: 22703858
Anti-CD3 drug keeps diabetes at bay. PMID: 31578500
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. PMID: 32789003
Prevention versus intervention of type 1 diabetes. PMID: 23803322
Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance. PMID: 31523950
Prospects for therapeutic tolerance in humans. PMID: 24378931
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. PMID: 31157632
Anti-CD3 clinical trials in type 1 diabetes mellitus. PMID: 23726024
Microbiota control immune regulation in humanized mice. PMID: 29093268
Primary and secondary prevention of Type 1 diabetes. PMID: 23231526
Immunotherapies currently in development for the treatment of type 1 diabetes. PMID: 26364507
Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. PMID: 25437293
Anti-CD3 mAbs for treatment of type 1 diabetes. PMID: 19319985
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. PMID: 28844471
Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. PMID: 23254986
100 YEARS OF INSULIN: Arresting or curing type 1 diabetes: an elusive goal, but closing the gap. PMID: 33729180
B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes. PMID: 33418839
A future for CD3 antibodies in immunotherapy of type 1 diabetes. PMID: 30612137
[One step towards restoration of self-tolerance in human autoimmune diseases]. PMID: 17291426
Immune therapy and β-cell death in type 1 diabetes. PMID: 23423576
Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). PMID: 18817833
CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. PMID: 23804274
T cell-regulating therapies for autoimmune diseases take FDA rejection in stride. PMID: 34363024
Immunotherapy for Type 1 diabetes: getting beyond a negative first impression. PMID: 22853748
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. PMID: 36951997
How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic? PMID: 33632743
Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance. PMID: 16187942
Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia. PMID: 32483610
Type 1 diabetes pathogenesis - Prevention??? PMID: 25941654
Modulating the immune system to delay the clinical onset of type 1 diabetes. PMID: 31980070
Antibody-based therapeutics to watch in 2011. PMID: 21051951
The compelling case for anti-CD3 in type 1 diabetes. PMID: 24158991
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials. PMID: 36896700
Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes. PMID: 33007232
Prevention and reversal of type 1 diabetes--past challenges and future opportunities. PMID: 25998292
Anti-CD3 antibodies for type 1 diabetes: beyond expectations. PMID: 21719098
Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 Diabetes. PMID: 34704801
Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes. PMID: 36415095
An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes. PMID: 30556344
Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects. PMID: 36505477
Depleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere? PMID: 24158996
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. PMID: 29925930
Diabetes: type 1 diabetes mellitus--a door opening to a real therapy? PMID: 21878898
Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. PMID: 32439823
Humanized mice as a model for aberrant responses in human T cell immunotherapy. PMID: 24943216
Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials. PMID: 36741943
Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. PMID: 21038470
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. PMID: 19837003
Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes. PMID: 34493565
Analysis of human biologics with a mouse skin transplant model in humanized mice. PMID: 22900715
A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. PMID: 15919798
Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. PMID: 15589476